CA3244202A1 - DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF - Google Patents
DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOFInfo
- Publication number
- CA3244202A1 CA3244202A1 CA3244202A CA3244202A CA3244202A1 CA 3244202 A1 CA3244202 A1 CA 3244202A1 CA 3244202 A CA3244202 A CA 3244202A CA 3244202 A CA3244202 A CA 3244202A CA 3244202 A1 CA3244202 A1 CA 3244202A1
- Authority
- CA
- Canada
- Prior art keywords
- cariprazine
- composition according
- acid
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320706P | 2022-03-17 | 2022-03-17 | |
| US63/320,706 | 2022-03-17 | ||
| PCT/IL2023/050150 WO2023175598A1 (en) | 2022-03-17 | 2023-02-14 | Depot systems comprising cariprazine or salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244202A1 true CA3244202A1 (en) | 2023-09-21 |
Family
ID=88022782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244202A Pending CA3244202A1 (en) | 2022-03-17 | 2023-02-14 | DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11931357B2 (https=) |
| EP (1) | EP4493274A4 (https=) |
| JP (1) | JP2025509390A (https=) |
| CN (1) | CN119136804A (https=) |
| AU (1) | AU2023234747A1 (https=) |
| CA (1) | CA3244202A1 (https=) |
| IL (1) | IL315074A (https=) |
| MX (1) | MX2024011063A (https=) |
| WO (1) | WO2023175598A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
| US20230372331A1 (en) * | 2022-05-18 | 2023-11-23 | Anxo Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| CN119424341A (zh) * | 2023-08-02 | 2025-02-14 | 珠海市华海康医药科技有限责任公司 | 一种注射用药物缓释微球及其制备方法 |
| CN117137864A (zh) * | 2023-11-01 | 2023-12-01 | 山东则正医药技术有限公司 | 一种卡利拉嗪原位凝胶制剂及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN108261394B (zh) | 2017-01-04 | 2022-03-04 | 广东东阳光药业有限公司 | 一种盐酸卡利拉嗪注射制剂及其制备方法和用途 |
| HUP1700253A1 (hu) | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| US11344503B2 (en) * | 2019-12-13 | 2022-05-31 | Halo Science LLC | Cariprazine release formulations |
| WO2022003662A1 (en) | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| AU2023234747A1 (en) * | 2022-03-17 | 2024-09-12 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
-
2023
- 2023-02-14 AU AU2023234747A patent/AU2023234747A1/en active Pending
- 2023-02-14 MX MX2024011063A patent/MX2024011063A/es unknown
- 2023-02-14 US US18/109,328 patent/US11931357B2/en active Active
- 2023-02-14 JP JP2024553723A patent/JP2025509390A/ja active Pending
- 2023-02-14 CN CN202380028161.9A patent/CN119136804A/zh active Pending
- 2023-02-14 WO PCT/IL2023/050150 patent/WO2023175598A1/en not_active Ceased
- 2023-02-14 CA CA3244202A patent/CA3244202A1/en active Pending
- 2023-02-14 EP EP23770030.7A patent/EP4493274A4/en active Pending
- 2023-02-14 IL IL315074A patent/IL315074A/en unknown
-
2024
- 2024-02-08 US US18/436,682 patent/US12251380B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11931357B2 (en) | 2024-03-19 |
| CN119136804A (zh) | 2024-12-13 |
| EP4493274A1 (en) | 2025-01-22 |
| IL315074A (en) | 2024-10-01 |
| WO2023175598A1 (en) | 2023-09-21 |
| AU2023234747A1 (en) | 2024-09-12 |
| MX2024011063A (es) | 2024-09-23 |
| US20240238280A1 (en) | 2024-07-18 |
| JP2025509390A (ja) | 2025-04-11 |
| US20230293515A1 (en) | 2023-09-21 |
| EP4493274A4 (en) | 2026-03-18 |
| US12251380B2 (en) | 2025-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12251380B2 (en) | Depot systems comprising cariprazine or salts thereof | |
| WO2009060473A2 (en) | Injectable compositions, processes and uses thereof | |
| JP2010505819A (ja) | デポ型注射剤組成物とその調製方法 | |
| EP3360538B1 (en) | Injectable flowable composition comprising buprenorphine | |
| EP2582395B1 (en) | Methods for the preparation of injectable depot compositions | |
| EP2575890B1 (en) | Antipsychotic injectable depot composition | |
| CN1468090A (zh) | 缓释药物制剂及其施用方法 | |
| CN101854922A (zh) | 用于减轻、预防或治疗疼痛和炎症的具有不同释放曲线的长效制剂 | |
| EP4259093B1 (en) | Material and method for treating cancer | |
| US20240148653A1 (en) | Semaglutide depot systems and use thereof | |
| US20230256058A1 (en) | Low burst-release liraglutide depot systems | |
| CN113117092A (zh) | 一种非水缓释递药系统 | |
| WO2018108164A1 (zh) | 一种硼替佐米药物组合物及其应用 | |
| WO2023025272A1 (zh) | 一种小分子药物缓释递药系统 | |
| HK40116297A (zh) | 包含卡利拉嗪或其盐的储库系统 | |
| CN1850035A (zh) | 一种局部应用的抗生素的缓释制剂 | |
| TW202435885A (zh) | 卡利拉嗪(Cariprazine)之長效性注射用(LAI)組合物 | |
| TW202529795A (zh) | 新穎組成物 | |
| JP2025515960A (ja) | 医薬組成物 | |
| CN1850036A (zh) | 一种含喹诺酮类抗生素的缓释剂 | |
| KR20250069077A (ko) | 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도 | |
| TWI426929B (zh) | 持續性釋放之含抗生素醫藥組合物、製備法及其應用 | |
| HK40104236A (zh) | 索玛鲁肽贮库系统及其用途 | |
| CN1857218A (zh) | 含抗结核病药物的缓释剂 | |
| CN101045036A (zh) | 一种含亚硝脲类药物及拓扑酶抑制剂的缓释注射剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240814 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240816 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240816 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240816 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241107 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250210 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260422 |